Eligard Depot 22.5mg Injection

Manufacturer: Emcure Pharmaceuticals Ltd

Salt Composition : Leuprolide(22.5mg)

Prescription
Prescription Required: Consult the Doctor & Get Your ePrescription

Advanced prostatic cancer is a cancer (abnormal cell multiplication and differentiation) that originates in the prostate gland and spreads to the other parts of the body. It is characterized by the symptoms such as painful urination, decreased urine pressure, blood in the semen, bone pain, leg swelling, and weakness.


Do not receive ELIGARD 22.5MG INJECTION if you are allergic to Leuprolide, GnRH, GnRH agonist analogs.


Before receiving this medicine, inform your doctor if you have liver impairment, kidney impairment, congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, metastatic vertebral lesions, urinary tract obstruction, or diabetes.


Before receiving this medicine, inform your doctor if you have a history of seizures, epilepsy, cerebrovascular disorders, or central nervous system anomalies/tumours. ELIGARD 22.5MG INJECTION is not recommended for use in pregnant women, breastfeeding women, and children.


It should be used with caution in elderly patients (aged above 65 years). Consult your doctor before receiving.


The most common side effects associated with the use of ELIGARD 22.5MG INJECTION are general pain, reactions at the site of injection, hot flashes/sweating, gastrointestinal disorders, joint disorders, shrinking of testes, urinary disorders, infections in upper respiratory tract, and fatigue. Consult your doctor if any of these side effects worsens.


Basic Information

Mechanism Of Action

ELIGARD 22.5MG INJECTION helps in palliative treatment of advanced prostatic cancer where leuprolide works by blocking the secretion of gonadotropin releasing hormone (GnRH) following an initial stimulation, resulting in suppression of ovarian and testicular steroidogenesis (process of synthesis of steroid hormones), thereby relieving the symptoms associated with increased testosterone levels in advanced prostatic cancer.


Pharmacokinets

Leuprolide has a terminal elimination half-life of approximately three hours. Leuprolide administered as a 1 mg intravenous bolus in healthy males has a mean systemic clearance between 7.6 and 8.3 L/h. Leuprolide is considered extremely safe, with low dose-related toxicity and comparatively mild adverse effects.

Side Effects

COMMON

Hot flashes, sweating

General pain in the body (especially joint pain and back pain)

Pain at the site of injection

Gastrointestinal disorders

Respiratory disorders

Urinary disorders

Shrinking of testicles

Extreme weakness

Headache

Joint disorders

Dizziness

Other sleep disorders

Neuromuscular disorders

Skin reactions

Flu-syndrome

Dehydration

Muscle pain

Sensation of pins and needles

Lethargy

Constipation

Sinus headache

Influenza-like illness including influenza, nasopharyngitis, nasal congestion, upper respiratory tract infection, rhinorrhea, and viral upper respiratory tract infection

Cough

Hemorrhagic cystitis

High blood pressure

Rash

Urinary tract infection

Cystitis (an inflammatory condition of bladder)

Decreased haemoglobin

COPD (chronic obstructive pulmonary disease)

Breathlessness especially on exertion

Increased frequency of urination in night

Peripheral/pitting oedema (swelling in legs and feet due to water retention)

Coronary artery disease ( heart disease) characterized by angina (chest pain)

Itching

Hair loss

Pain in testicles

Clamminess

Breast enlargement in males

Reduced libido

RARE

Stop receiving ELIGARD 22.5MG INJECTION and contact your doctor if you experience any of the following side effects:

COPD (chronic obstructive pulmonary disease)

Coronary artery disease (heart disease) is characterized by angina (chest pain)

Cerebrovascular accident/transient ischemic attack (life-threatening events related to impaired heart function)

Pneumonia (a life-threatening lung disease)

Second primary neoplasm (cancer) including basal cell carcinoma, lung neoplasm, bladder transitional cell carcinoma, malignant melanoma, squamous cell carcinoma, non-Hodgkin’s lymphoma

Contra Indications

Contraindications to leuprolide therapy include hypersensitivity to leuprolide or any other gonadotropin-releasing hormone agonists. [13] This medication should not be used in women who are or may become pregnant. A negative pregnancy test is necessary before starting the medication.

Pregnancy Related Information

ELIGARD 22.5MG INJECTION is not recommended for use during pregnancy. Consult your doctor before receiving.


Breast Feeding Related Information

ELIGARD 22.5MG INJECTION is not recommended for use in breastfeeding women as it can pass through milk. Consult your doctor before receiving.

Indications

Leuprolide is a medication used in the management and treatment of prostate cancer, endometriosis, uterine fibroids, precocious puberty, and other sex hormone-related conditions. It is in the GnRH agonist class of medications.

Interactions

Drug-Drug Interaction: LEUPROLIDE may interact with heart rhythm problems treating drugs (quinidine, procainamide, disopyramide, amiodarone, sotalol), steroids (dexamethasone, methylprednisolone) and prednisone antibiotics (moxifloxacin), opioid pain killers (methadone) and antipsychotics (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline).

Drug-Food Interaction: No interactions found/established.

Drug-Disease Interaction: LEUPROLIDE should be used with caution in cases of liver or kidney diseases, heart diseases, recent heart attack, depression, brain tumours, electrolyte imbalance, diabetes, fits, weak bones and high cholesterol levels.

Drug-Drug Interactions Checker List:

QUINIDINE

PROCAINAMIDE

DISOPYRAMIDE

AMIODARONE

DEXAMETHASONE

METHYLPREDNISOLONE

PREDNISOLONE

MOXIFLOXACIN

METHADONE

CITALOPRAM

ESCITALOPRAM

FLUOXETINE

FLUVOXAMINE

PAROXETINE

SERTRALINE

Storage Requirements

Keep ELIGARD 22.5MG INJECTION out of reach of children

Store between 2-8°C

Effects Of Overdose

ELIGARD 22.5MG INJECTION will be given to you only by a doctor or nurse in a hospital, and so it is unlikely to receive an overdose. If you or anyone else accidentally receives too much of this medicine, consult your doctor immediately or visit the nearby hospital. Symptoms of overdose are shortness of breath, decreased activity, and increased scratching.


How To Use

ELIGARD 22.5MG INJECTION will be administered to you only by a doctor or a nurse intramuscularly (into the muscle) or subcutaneously (under the skin). Your doctor will administer the correct dose and duration for you depending upon your age, body weight and disease condition.

FAQs

What ELIGARD 22.5MG INJECTION is used for?

ELIGARD 22.5MG INJECTION for palliative treatment (relieving symptoms and minimize the associated suffering) of advanced prostatic cancer. Consult your doctor before receiving.

What side effects are seen with ELIGARD 22.5MG INJECTION?

The most common side effects associated with the use of ELIGARD 22.5MG INJECTION are general pain, reactions at the site of injection, hot flashes/sweating, gastrointestinal disorders, joint disorders, shrinking of testes, urinary disorders, infections in the upper respiratory tract, and fatigue. Consult your doctor if any of these symptoms worsens.

Who should avoid receiving ELIGARD 22.5MG INJECTION?

Do not receive ELIGARD 22.5MG INJECTION if you are allergic to leuprolide, GnRH, GnRH agonist analogs. It is not recommended for use in pregnant women, breastfeeding women, and children. Consult your doctor before receiving.

Is ELIGARD 22.5MG INJECTION safe to use in children?

ELIGARD 22.5MG INJECTION is not recommended for use in children because the safety and effectiveness of this medicine have not been established in this population. Consult your doctor before receiving.